{"doi":"10.1188/18.cjon.542-548","title":"Afatinib Therapy: Practical Management of Adverse Events With an Oral Agent for Non-Small Cell Lung Cancer Treatment","abstract":null,"journal":"Clinical Journal of Oncology Nursing","year":2018,"id":640448,"datarank":0.47670807455219194,"base_score":3.1780538303479458,"endowment":3.1780538303479458,"self_citation_contribution":0.47670807455219194,"citation_network_contribution":0.0,"self_endowment_contribution":0.47670807455219194,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":23,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1664469,"name":"Christine Andan","orcid":null,"position":1,"is_corresponding":false},{"id":1664470,"name":"Rajesh Lalla","orcid":null,"position":2,"is_corresponding":false},{"id":1664471,"name":"Mario Lacouture","orcid":null,"position":3,"is_corresponding":false},{"id":1664472,"name":"Dennis O’Brien","orcid":null,"position":4,"is_corresponding":false},{"id":1664473,"name":"Lecia Sequist","orcid":null,"position":5,"is_corresponding":false},{"id":1359480,"name":"Rebecca Edwards","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Afatinib Therapy: Practical Management of Adverse Events With an Oral Agent for Non-Small Cell Lung Cancer Treatment","abstract":"BACKGROUND: Afatinib is an oral, irreversible ErbB family blocker indicated for first-line treatment of metastatic non-small cell lung cancer (NSCLC) in patients with non-resistant epidermal growth factor receptor (EGFR) mutations. Afatinib is also approved for the treatment of metastatic squamous NSCLC following progression on platinum-based chemotherapy. Common afatinib-associated toxicities include gastrointestinal and dermatologic events, which can be dose limiting. OBJECTIVES: In this review, the authors describe clinical trial experiences with afatinib, as well as best practices and practical approaches to the management of afatinib-associated adverse events in EGFR mutation-positive NSCLC. METHODS: Safety and tolerability data from phase 3 trials of afatinib were reviewed, together with real-life experiences from the authors' clinical practices. FINDINGS: Patient education, combined with early assessment and effective management of afatinib-related adverse events as well as dose- reduction strategies, allows patients to continue treatment and maximize the clinical benefits of afatinib.","is_dataset_classified":null,"base_score":3.1780538303479458,"endowment":3.1780538303479458,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"30239509","pmcid":"PMC9116182","openalex_id":"https://openalex.org/W2889664788","authors":[],"funders":[{"funder_name":"NCI NIH HHS","grant_id":"P30 CA008748","title":null}],"total_grants":1,"fwci":1.2774,"citation_percentile":0.80707641,"influential_citations":1,"citation_trend":[{"year":2019,"count":2},{"year":2020,"count":5},{"year":2021,"count":1},{"year":2022,"count":3},{"year":2023,"count":4},{"year":2024,"count":3},{"year":2025,"count":1},{"year":2026,"count":4}],"oa_status":"green","license":null,"oa_locations":[{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/9116182","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9116182","host_type":"GREEN"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/9116182","host_type":"repository"},{"url":"http://cjon.ons.org/cjon/22/5/afatinib-therapy-practical-management-adverse-events-oral-agent-non-small-cell-lung-cancer","host_type":"publisher"},{"url":"https://doi.org/10.1188/18.cjon.542-548","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/30239509","host_type":"repository"}],"fields_of_study":["Lung Cancer Treatments and Mutations","Fibroblast Growth Factor Research","Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis","Medicine"],"mesh_terms":["Afatinib","Adult","Aged","Aged, 80 and over","Antineoplastic Combined Chemotherapy Protocols","Carcinoma, Non-Small-Cell Lung","Dose-Response Relationship, Drug","Education, Nursing, Continuing","Female","Humans","Male","Middle Aged","Mutation","Protein Kinase Inhibitors","Drug-Related Side Effects and Adverse Reactions","ErbB Receptors"],"keywords":["Afatinib","Medicine","Tolerability","Adverse effect","Oncology","Lung cancer","Internal medicine","Epidermal growth factor receptor","Clinical trial","Intensive care medicine","Cancer","Erlotinib","Non-small cell lung cancer","Adverse Events","Dose Reduction"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[{"name":"nct"}],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-07T11:57:58.205716Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}